Article

Effect of TRPM8 and TRPA1 Polymorphisms on COPD Predisposition and Lung Function in COPD Patients

Denis E. Naumov 1,*, Olesya O. Kotova 1, O., Dina A. Gassan 1, Ivana Y. Sugaylo 1, Evgeniya Y. Afanas’eva 1, Elizaveta G. Sheludko 1 and Juliy M. Perelman 2

1 Far Eastern Scientific Center of Physiology and Pathology of Respiration, Laboratory of Molecular and Translational Research, 675000 Blagoveschensk, Russia; foxy_voxy_on@mail.ru (O.O.K.); dani-sh@mail.ru (D.A.G.); ivanka_888@mail.ru (I.Y.S.); evgenijananev@yandex.ru (E.Y.A.); liza.sheludko@mail.ru (E.G.S.)

2 Far Eastern Scientific Center of Physiology and Pathology of Respiration, Laboratory of Functional Research of the Respiratory System, 675000 Blagoveschensk, Russia; jperelman@mail.ru

* Correspondence: denn1985@bk.ru; Tel.: +7-914-561-6952

Abstract: Certain transient receptor potential (TRP) channels including TRPM8 and TRPA1 are widely expressed in the respiratory tract and have been shown to be the receptors of cigarette smoke and particulate matter—the main causative factors of chronic obstructive pulmonary disease (COPD). The aim of the study was to investigate the effect of TRPM8 and TRPA1 polymorphisms on COPD predisposition and lung function in COPD patients. The study enrolled 143 COPD patients and 104 smokers with post-bronchodilator forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) > 70%. Lung function was measured by spirometry. TRPM8 and TRPA1 polymorphisms were genotyped by LATE-PCR. None of the polymorphisms significantly influenced COPD predisposition after correction for covariates and multiple testing. Among COPD patients, the TT genotype of TRPA1 rs7819749 was significantly associated with higher degree of bronchial obstruction. In addition, we established that carriers of the C allele of TRPM8 rs11562975 more commonly had post-bronchodilator FEV1 < 60% (OR 3.2, 95%CI (1.14–8.94), p = 0.03) and revealed the effect of TRPA1 rs959976 and TRPM8 rs17865682 on bronchodilator response in COPD. Thus, the obtained results suggest possible involvement of TRPM8 and TRPA1 in COPD pathogenesis, indicating the necessity to further investigate their functional role in this pathology.

Keywords: COPD; lung function; smoking; TRPM8; TRPA1; polymorphism

1. Introduction

According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, chronic obstructive pulmonary disease (COPD) is a common, preventable and treatable disease characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases [1]. In 2010, the estimated worldwide COPD prevalence was 11.7% (8.4%–15.0%), with the highest values in the USA (15.2% (14.9%–15.5%)) and the lowest in South-East Asia (9.7% (9.3%–10.1%)) [2]. An increase of 68.9% in COPD cases has been observed over a twenty-year period worldwide, mainly at the expense of urban populations [2]. Although the disease is defined as ‘treatable’, the effectiveness of the modern therapeutic approaches remains relatively limited. Despite proper treatment, some patients continue to experience frequent exacerbations with progressive loss of lung function which eventually leads to disability and premature mortality. Since 2010, COPD has become the third leading cause of death, with mortality rate up to 141 per 100,000 person-years, in some countries [3]. The presence of different clinical phenotypes of COPD with corresponding underlying pathogenesis implies the urge for a personalized approach in disease management and the discovery of novel pharmacological targets [4].
Tobacco smoking is widely considered to be among the major risk factors for COPD. However, in ever-smokers, only 17.8% were reported to have COPD. Nevertheless, among non-smokers the prevalence of COPD is significantly lower (6.4%) [5]. In the latter category of patient, a substantial role in COPD development belongs to occupational exposures and general air pollution, including traffic, biomass and secondhand smoke [6].

Usually, cigarette smoke and air pollutants are thought to exert their effect on the airways in a non-specific manner, promoting reactive oxygen species (ROS) production, release of damage-associated molecular pattern molecules and activation of inflammatory cells. However, a growing body of data generated during the latest decade has provided us with new ideas of how transient receptor potential (TRP) channels may mediate the effect of cigarette smoke and particulate matter on living cells and so be potentially important in COPD pathogenesis.

TRP channels represent a family of receptor proteins sensitive to a variety of exo- and endogenous stimuli of a physical and chemical nature [7]. Up to date, four main TRP channels have been established as receptors of smoke constituents and particles: TRPM8, TRPA1, TRPV1 and TRPV4. These channels may be found throughout the respiratory system on different cell types, including nerve endings, bronchial and alveolar epithelium, macrophages and other cells of the immune system [8]. Among them, TRPA1 is the most consistently reported receptor of cigarette smoke, sensitive to such toxic carbonyl compounds as formaldehyde and acrolein [9]. Along with TRPA1, TRPM8, TRPV1 and TRPV4 were also found to be sensitive to cigarette smoke and particulate matter [10–14]. Besides, TRPV1, TRPM8 and, to a lesser extent, TRPA1 were capable of activation under exposition with coal fly ash [15].

There are few studies which have previously investigated an association between TRP genetic polymorphisms and COPD. The first, conducted by Zhu et al., utilized both family-based and case-control design and revealed four single-nucleotide polymorphisms (SNPs) of TRPV4 persistently associated with COPD [16]. Another two studies established that the polymorphisms of TRPM8 and TRPV1 may influence COPD predisposition in the Chinese Han population [17,18]. However, TRPM8 or TRPV1 variants that showed the most significant associations are almost absent in Europeans due to extremely low minor allele frequency, so it is difficult to replicate or extrapolate the obtained results. Considering these facts, the aim of the present study was to investigate the effect of TRPM8 and TRPA1 polymorphisms on COPD predisposition and lung function in a European population.

2. Materials and Methods

2.1. Study Population

A total of 247 unrelated subjects including 143 COPD patients from the inpatient department of the Far Eastern Scientific Center of Physiology and Pathology of Respiration and 104 healthy controls were enrolled in the study. All the enrolled persons were Europeans living in the Amur Oblast of Russia. COPD was diagnosed by standard criteria (symptoms, risk factors, post-bronchodilator forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) < 70%) according to GOLD guidelines [1]. Subjects for the control group were recruited from active smokers with FEV1/FVC > 70% undergoing regular medical examination in the outpatient department. Subjects without smoking history or those who had any other respiratory pathology, besides COPD, were not included in the study. The study was approved by the local Ethics Committee of the Far Eastern Scientific Center of Physiology and Pathology of Respiration (Ethics approval No. 131; 11 January 2019) and conducted in accordance with the Declaration of Helsinki—Ethical Principles for Medical Research Involving Human Subjects (revised in 2013). An informed consent was obtained from all the participants before inclusion in the study.

2.2. Lung Function Measurement

Lung function was measured by standard spirometry using an Easy-on PC spirometer (ndd Medizintechnik AG, Zurich, Switzerland) in accordance with American Thoracic
Society/European Respiratory Society (ATS/ERS) guidelines [19]. Values of forced expiratory volume in one second (FEV1), forced vital capacity (FVC), FEV1/FVC ratio, peak expiratory flow (PEF), forced expiratory flow at 50% and 75% of FVC (FEF50 and FEF75) and maximum mid-expiratory flow (MMEF) were determined before and 15 min after four puffs of salbutamol (400 µg). Positive response to bronchodilator was defined as an increase in FEV1 by ≥12% or ≥200 mL 15 min after salbutamol inhalation.

2.3. Genotyping

Genomic DNA was extracted from whole blood using the DNK-Extran-1 kits (Syntol LLC, Moscow, Russia). Five TRPM8 and six TRPA1 polymorphisms were selected based on the combined approach considering minor allele frequency (>0.05), evidence of associations from the previous studies and functional significance predicted by the bioinformatic tool SNP Function Prediction [20]. Brief characteristics of the selected polymorphisms are summarized in Table 1. The polymorphisms were genotyped by LATE-PCR with melting analysis of molecular beacon probes [21]. PCR was performed on CFX96 Touch Real-Time PCR System (Bio-Rad, Hercules, CA, USA) using PCR-RV reagent kits (Syntol LLC, Moscow, Russia). The reaction mixture contained: DNA—50 ng, 1X PCR-buffer, MgCl2—2.5 mM, dNTP—0.25 mM, limiting primer—0.02 µM, excessive primer—0.5 µM, molecular beacon probe—0.5 µM, Hot-Start Taq-polymerase—1 U, ddH2O—up to 25 µL. Thermal cycling was performed under the following conditions for each polymorphism: initial denaturation at 96 °C for 1.5 min; first 25 cycles—denaturation at 96 °C for 1 s, annealing/extension at primer-specific temperature (Ta1) for 15 s; following 45 cycles—denaturation at 96 °C for 1 s, annealing/extension at primer-specific temperature (Ta2) for 15 s; final extension at 72 °C for 1 min. Ramp rate was set to 3 °C/s. Melting analysis of molecular beacon was performed immediately after the thermal cycling but was preceded by a denaturation step at 96 °C for 3 min and hybridization at 30 °C for 3 min. Then, PCR tubes were heated stepwise from 30 °C to 70 °C at a rate of 0.5 °C per step with 5 s hold at each temperature. A fluorescent signal in the FAM channel was detected at the end of each step. The form of generated melting curves allowed for allelic discrimination relying on the corresponding peaks on the negative first derivative of the fluorescence-versus-temperature plots (Figure 1). Detailed information on polymorphism genotyping including oligonucleotide sequences, concentrations and thermal cycling conditions is available in Supplementary Table S1.

Table 1. Brief characteristics of the studied polymorphisms.

| RefSNP No. | Gene | Chromosome and Position (GRCh38) | Region | Nucleotide (Amino-acid) Substitution | Selection Criteria |
|------------|------|---------------------------------|--------|-------------------------------------|--------------------|
| rs7577262  | TRPM8| 2:233910224                     | 5′-near gene | g.233910224G >A                 | [22,23]             |
| rs10166942 | TRPM8| 2:233916448                     | 5′-near gene | c.-990T > C                        | [24–26]             |
| rs11562975 | TRPM8| 2:233949006                     | exon    | c.750G > C (p.Leu250 =)            | [27]                |
| rs2052030  | TRPM8| 2:234018966                     | 3′-UTR   | c.*1710C > G                       | possible miRNA binding site [28] |
| rs17865682 | TRPM8| 2:234019581                     | 3′-near gene | c.2325A > G                        | [29]                |
| rs920829   | TRPA1| 8:72065468                      | exon    | c.558A > C (p.Lys186Asn)           | [30,31]             |
| rs7819749  | TRPA1| 8:72063566                      | exon    | c.539G > A (p.Glu179Lys)           | missense SNP, possible exonic splicing silencer [31] |
| rs4738202  | TRPA1| 8:72028626                      | intron  | c.2937+1275T > C                  | [31]                |
| rs959976   | TRPA1| 8:72023910                      | exon    | c.3053A > G (p.His1018Arg)         | [32]                |
| rs959974   | TRPA1| 8:72023604                      | intron  | c.3149+210C > A                   | possible miRNA binding site [31] |
| rs6996723  | TRPA1| 8:72021397                      | 3′-UTR   | c.*1509G > A                      |                    |
Figure 1. Representative melting curves corresponding to three different genotypes of TRPM8 rs2052030 polymorphism. Single peaks at 60 °C and 50 °C correspond to the CC and GG genotypes, respectively. Simultaneous presence of both peaks indicates the heterozygous CG genotype.

2.4. Statistical Analysis

Statistical analysis was performed using Statistica version 10.0 software (StatSoft Inc., Tulsa, OK, USA). Kolmogorov–Smirnov and Shapiro–Wilk tests were used to determine whether the data are normally distributed. Due to non-normal distribution, quantitative data are presented as median (interquartile range). Mann-Whitney U test was used for pair-wise comparisons of quantitative variables. Frequency distribution of the genotypes and alleles was presented as percentage. Hardy–Weinberg equilibrium between observed and expected genotype frequencies was evaluated by Pearson’s chi-square test. Associations between categorical variables were assessed by Pearson’s chi-square test or Fisher’s exact test. Adjustment for covariates was performed in logistic regression analysis. Benjamini-Hochberg False Discovery Rate (FDR) was used for multiple testing correction. p-value < 0.05 was considered statistically significant and FDR corrected p-value < 0.25 was considered as a trend.

3. Results

3.1. Clinical and Functional Characteristics of the Studied Subjects

Differences in clinical parameters, smoking history and lung function between the case and control groups are shown in Table 2. COPD patients were significantly older, had longer exposition to cigarette smoke, marked bronchial obstruction and higher response to bronchodilator.

3.2. Role of TRPM8 and TRPA1 Polymorphisms in COPD Predisposition

Genotype frequencies for each of the studied polymorphisms were in Hardy–Weinberg equilibrium both in case and control groups. Generally, the differences in genotype frequencies for the studied polymorphisms were tested in the codominant genetic model. However, in cases in which less than five minor allele homozygotes were detected in either group, they were merged with heterozygotes and the dominant genetic model was employed (Table 3).
Table 2. Clinical and Functional Characteristics of the Studied Groups.

| Characteristics                                      | Chronic Obstructive Pulmonary Disease (COPD) (n = 143) | Healthy Smokers (n = 104) | p-Value |
|------------------------------------------------------|------------------------------------------------------|---------------------------|---------|
| Age (years)                                          | 61.0 (56.0–66.0)                                     | 43.5 (34.5–52.0)          | <0.001  |
| Gender (M/F, %)                                      | 85/15                                                | 74/26                     | 0.03    |
| Pack-year index                                      | 40.0 (26.0–45.0)                                    | 15.0 (6.0–22.5)           | <0.001  |
| Pack-year ≥ 10 (%)                                   | 97                                                   | 67                        | <0.001  |
| Forced expiratory volume in one second (FEV1) (%) pred. | 40.2 (30.3–58.1)                                    | 100.0 (92.8–114.5)        | <0.001  |
| Forced vital capacity (FVC) (%) pred.                | 60.1 (47.0–75.7)                                    | 104.5 (96.0–116.5)        | <0.001  |
| FEV1/FVC (%)                                         | 46.2 (38.0–54.2)                                    | 80.4 (76.1–85.2)          | <0.001  |
| Peak expiratory flow (PEF) (%) pred.                 | 41.0 (31.7–55.0)                                    | 95.2 (86.5–111.0)         | <0.001  |
| Forced expiratory flow (FEF)50 (%) pred.             | 13.0 (8.0–23.3)                                      | 87.5 (73.0–101.5)         | <0.001  |
| PEF75 (%)                                            | 11.9 (1.4–20.9)                                     | 76.7 (60.7–88.8)          | <0.001  |
| Maximum mid-expiratory flow (MMEF) (%) pred.         | 15.0 (11.1–23.5)                                    | 85.8 (68.7–100.0)         | <0.001  |
| FEV1 (%)                                             | 13.7 (5.0–23.0)                                     | 5.1 (2.5–8.8)             | <0.001  |
| FVC (%)                                              | 14.0 (3.1–55.7)                                     | 95.2 (86.5–111.0)         | <0.001  |
| PostBD-FEV1 (%)                                      | 48.0 (36.4–62.5)                                    | 103.1 (94.3–115.0)        | <0.001  |
| PostBD-FEV1/FVC (%)                                  | 48.3 (40.4–55.7)                                    | 79.8 (75.0–82.7)          | <0.001  |

Data are presented as median (interquartile range) or as percentage. Response to bronchodilator was assessed in 42 control subjects only.

Table 3. Genotype frequencies of the studied polymorphisms in COPD patients and control group.

| Polymorphism | Genotypes | COPD | Healthy Smokers | p-Value | p-Value Adjusted 2 | False Discovery Rate (FDR) p |
|--------------|-----------|-----|-----------------|---------|-------------------|-----------------------------|
| TRPM8 rs7577262 | GG 118 (82.5%) | 82 (78.8%) | 0.47 | 0.79 | 0.98 |
|              | GA 24 (16.8%) | 19 (18.3%) |              |         |                   |                             |
|              | AA 1 (0.7%) | 3 (2.9%) |              |         |                   |                             |
| TRPM8 rs10166942 | GG 113 (79.0%) | 86 (82.7%) | 0.89 | 0.79 | 0.98 |
|              | GC 28 (19.6%) | 17 (16.3%) | 0.47 | 0.49 | 0.92 |
| TRPM8 rs11562975 | GG 2 (1.4%) | 1 (1.0%) | 0.01 | 0.08 | 0.30 |
| TRPM8 rs2052000 | GC 48 (33.6%) | 54 (51.9%) | 0.01 | 0.08 | 0.30 |
| TRPM8 rs17865682 | AA 105 (73.4%) | 75 (72.1%) | 0.82 | 0.61 | 0.98 |
|              | GC 33 (23.1%) | 27 (26.0%) | 0.10 | 0.15 | 0.43 |
|             | GG 5 (3.5%) | 2 (1.9%) | 0.87 | 0.98 | 0.98 |
| TRPA1 rs920829 | AA 2 (1.4%) | 3 (2.9%) | 0.71 | 0.85 | 0.98 |
|              | AG 30 (21.0%) | 30 (28.8%) | 0.71 | 0.85 | 0.98 |
| TRPA1 rs7819749 | GA 111 (77.6%) | 71 (68.3%) | 0.01 | 0.08 | 0.30 |
|              | GG 60 (42.0%) | 46 (44.2%) | 0.10 | 0.15 | 0.43 |
| TRPA1 rs4738202 | AA 9 (6.3%) | 8 (7.7%) | 0.87 | 0.98 | 0.98 |
|              | AG 51 (35.7%) | 41 (39.4%) | 0.71 | 0.85 | 0.98 |
| TRPA1 rs959976 | AA 92 (64.3%) | 61 (58.7%) | 0.36 | 0.17 | 0.43 |
|              | AG 44 (30.8%) | 39 (37.5%) |              |         |                   |                             |
| TRPA1 rs959974 | GG 7 (4.9%) | 4 (3.8%) | 0.86 | 0.97 | 0.98 |
|              | GT 28 (19.6%) | 20 (19.2%) | 0.86 | 0.97 | 0.98 |
| TRPA1 rs6996723 | GA 34 (23.8%) | 25 (24.0%) | 0.89 | 0.43 | 0.92 |

1 Polymorphisms with less than five observations for minor allele homozygotes in either group were analyzed in the dominant model; 2 after adjustment for sex, age and pack-year index.
We found that prior to correction for multiple comparisons or possible confounders, TRPM8 rs2052030 was significantly associated with COPD. Despite the fact that the significance of this association was lost after the adjustments, we additionally estimated the potential effect of rs2052030 on COPD predisposition under other genetic models (Table 4).

As a result, it was established that the effect of TRPM8 rs2052030 on COPD was best described by the over-dominant model. The heterozygous CG genotype was prevalent among control group but relatively underrepresented in the studied COPD patients. This association retained its significance after adjustment for sex, age and pack-year index, but was not significant after FDR correction for multiple comparisons (p = 0.22).

Table 4. Association Between TRPM8 rs2052030 and COPD Under Different Genetic Models.

| Genetic Model    | Genotypes        | OR (95%CI)   | p-Value | OR (95%CI) Adjusted | p-Value Adjusted | FDR p |
|------------------|------------------|--------------|---------|---------------------|------------------|-------|
| Dominant         | CC vs. CG+GG     | 0.56         | 0.03    | 0.47                | 0.03             | 0.22  |
| Recessive        | CC+CG vs. GG     | 1.77         | 0.34    | 0.94                | 0.93             | 0.98  |
| Over-dominant    | CC+GG vs. CG     | 0.47         | 0.004   | 0.47                | 0.03             | 0.22  |
| Log-additive     |                  | 0.78         | 0.21    | 0.60                | 0.07             | 0.30  |

1 After adjustment for sex, age and pack-year index.

3.3. Effect of TRPM8 and TRPA1 Polymorphisms on Lung Function in COPD

We also tested TRPM8 and TRPA1 polymorphisms for their potential effect on baseline and post-bronchodilator lung function. TRPA1 rs7819749 and TRPA1 rs959974 appeared to have the most marked influence on the degree of bronchial obstruction. The T allele of TRPA1 rs7819749 had detrimental effect on lung function in COPD. Generally, the heterozygotes and, especially, TT homozygotes had lower values of spirometric parameters than the patients with the GG genotype. Similar effects were observed for TRPA1 rs959974 polymorphism with probable pathogenic effect of the G allele. However, in this case there was only a trend for association (Figure 2).

Figure 2. Effect of TRPA1 rs7819749 (A) and TRPA1 rs959974 (B) polymorphisms on baseline and post-bronchodilator (BD) FEV1/FVC in the studied COPD patients (n = 143). The results are presented as median, lower and upper quartiles. Denoted levels of significance are FDR corrected and correspond to the differences in FEV1/FVC between homozygous genotypes.

Given the apparent trend of the relationship between lung function parameters and the number of risk alleles for each of the three polymorphisms, we applied Kendall’s tau test to measure the significance of these correlations. As a result, we established a tendency to enhanced bronchial obstruction with the increase in the number of risk alleles for TRPM8 rs2052030 (G allele), TRPA1 rs7819749 (T allele) and TRPA1 rs959974 (G allele). The obtained correlations and FDR corrected p-values are shown in Figure 3.
Despite that there were no obvious and strong associations with lung function for TRPM8 rs11562975 in COPD, we took a closer look at this polymorphism since its influence on FEV1 and FEV1/FVC was established in our previous studies in asthma patients, including those with smoking history > 10 pack-years [28,33]. In accordance with these data, we noticed that in COPD patients the C allele of TRPM8 rs11562975 had a trend to association with lower post-bronchodilator FEV1/FVC (GG—48.9 (41.4–55.8)%, GC—45.7 (38.1–50.9)%, CC—35.2 (32.7–37.7)%). The CC genotype seemed to have the most profound effect on FEV1/FVC; however, this was not significant due to the low number of observations (n = 2). At the same time, analysis carried out in the dominant genetic model (GG vs. GC+CC) revealed the borderline significance for between-genotype difference of FEV1/FVC (48.9 (41.4–55.8)% vs. 43.9 (37.3–49.8)%, p = 0.05). Next, we tested the association of TRPM8 rs11562975 with post-bronchodilator FEV1 < 60%. This cut-off value was set to correspond to the previous finding in smoking asthma patients. The GC and CC genotypes in combination were found in 26.6% of the patients with FEV1 < 60% and only in 10.2% of the patients with FEV1 ≥ 60% and so increased the odds of having FEV1 < 60% (OR 3.2, 95%CI (1.14–9.67), p = 0.03). This association remained significant after correction for sex, age, pack year index (adjusted OR 3.3, 95%CI (1.15–9.67), p = 0.03). Unlike in COPD patients, we did not find any associations of the studied polymorphisms with lung function parameters in healthy smokers.

### 3.4. Associations of TRPM8 and TRPA1 Polymorphisms with the Airway Response to Bronchodilator

In the COPD group, 58.7% of patients had positive response to salbutamol, which is considered to be associated with better prognosis in terms of reduced risk of severe acute exacerbations [34]. The TRPA1 rs9599974 polymorphism significantly influenced the response both qualitatively and quantitatively. The heterozygous AG genotype prevailed among the patients with positive response (40.5% vs. 17.0%) while the AA and GG genotypes were more frequent in in non-responders (OR 3.3, 95%CI (1.49–7.69), p = 0.003; FDR p = 0.02). This effect was independent of sex, age, pack-year index and baseline FEV1 (adjusted OR 3.6, 95%CI (1.51–8.33), p = 0.003). Carriers of the heterozygous genotype had the highest bronchodilator response (ΔFEV1 17.3 (12.1–27.9)%) when compared with the AA (12.1 (4.2–22.8)%, p = 0.02) or GG genotypes (2.7 (0.1–23.0)%, p = 0.04), whereas the difference between the homozygous genotypes was not significant.

Polymorphism rs17865682 of TRPM8 gene also affected salbutamol response, measured qualitatively. The AA genotype more frequently occurred in the group with positive response both qualitatively and quantitatively. The heterozygous AG genotype prevailed among the patients with positive response (40.5% vs. 17.0%) while the AA and GG genotypes were more frequent in in non-responders (OR 3.3, 95%CI (1.49–7.69), p = 0.003; FDR p = 0.02). This effect was independent of sex, age, pack-year index and baseline FEV1 (adjusted OR 3.6, 95%CI (1.51–8.33), p = 0.003). Carriers of the heterozygous genotype had the highest bronchodilator response (ΔFEV1 17.3 (12.1–27.9)%) when compared with the AA (12.1 (4.2–22.8)%, p = 0.02) or GG genotypes (2.7 (0.1–23.0)%, p = 0.04), whereas the difference between the homozygous genotypes was not significant.

Polymorphism rs17865682 of TRPM8 gene also affected salbutamol response, measured qualitatively. The AA genotype more frequently occurred in the group with positive response both qualitatively and quantitatively. The heterozygous AG genotype prevailed among the patients with positive response (40.5% vs. 17.0%) while the AA and GG genotypes were more frequent in in non-responders (OR 3.3, 95%CI (1.49–7.69), p = 0.003; FDR p = 0.02). This effect was independent of sex, age, pack-year index and baseline FEV1 (adjusted OR 3.6, 95%CI (1.51–8.33), p = 0.003). Carriers of the heterozygous genotype had the highest bronchodilator response (ΔFEV1 17.3 (12.1–27.9)%) when compared with the AA (12.1 (4.2–22.8)%, p = 0.02) or GG genotypes (2.7 (0.1–23.0)%, p = 0.04), whereas the difference between the homozygous genotypes was not significant.

Polymorphism rs17865682 of TRPM8 gene also affected salbutamol response, measured qualitatively. The AA genotype more frequently occurred in the group with positive response both qualitatively and quantitatively. The heterozygous AG genotype prevailed among the patients with positive response (40.5% vs. 17.0%) while the AA and GG genotypes were more frequent in in non-responders (OR 3.3, 95%CI (1.49–7.69), p = 0.003; FDR p = 0.02). This effect was independent of sex, age, pack-year index and baseline FEV1 (adjusted OR 3.6, 95%CI (1.51–8.33), p = 0.003). Carriers of the heterozygous genotype had the highest bronchodilator response (ΔFEV1 17.3 (12.1–27.9)%) when compared with the AA (12.1 (4.2–22.8)%, p = 0.02) or GG genotypes (2.7 (0.1–23.0)%, p = 0.04), whereas the difference between the homozygous genotypes was not significant.

Polymorphism rs17865682 of TRPM8 gene also affected salbutamol response, measured qualitatively. The AA genotype more frequently occurred in the group with positive response both qualitatively and quantitatively. The heterozygous AG genotype prevailed among the patients with positive response (40.5% vs. 17.0%) while the AA and GG genotypes were more frequent in in non-responders (OR 3.3, 95%CI (1.49–7.69), p = 0.003; FDR p = 0.02). This effect was independent of sex, age, pack-year index and baseline FEV1 (adjusted OR 3.6, 95%CI (1.51–8.33), p = 0.003). Carriers of the heterozygous genotype had the highest bronchodilator response (ΔFEV1 17.3 (12.1–27.9)%) when compared with the AA (12.1 (4.2–22.8)%, p = 0.02) or GG genotypes (2.7 (0.1–23.0)%, p = 0.04), whereas the difference between the homozygous genotypes was not significant.
response (83.3% vs. 59.3%) while the AG and GG genotypes were prevalent among non-responders (33.9% vs. 15.5%, 6.8% vs. 1.2%, respectively). This association was significant after analysis under the dominant model (AA vs. AG+GG). Carriage of the AG or GG genotype increased the odds of being unresponsive to salbutamol in the COPD patients (OR 3.4, 95%CI (1.59–7.69), \( p = 0.002 \), FDR \( p = 0.02 \), even after correction for sex, age, pack-year index and baseline FEV1 (adjusted OR 4.2, 95%CI (1.79–10.0), \( p < 0.001 \)). Nevertheless, the difference in AFEV1 between the AA and AG+GG carriers showed only a trend toward statistical significance (15.7 (6.0–23.8)% vs. 8.8 (2.7–17.6)%, \( p = 0.06 \)).

4. Discussion

Considering the strong evidence for the role of smoking and particulate matter in COPD pathogenesis, the study of molecular mechanisms related to the reception of these detrimental environmental factors is highly justified. TRPM8 and TRPA1 cation channels are polymodal receptors widely expressed in the respiratory tract and sensitive to cigarette smoke and particulate matter. Indeed, according to the previously conducted research, TRPM8 and TRPA1 are likely to be involved in the development of chronic obstructive respiratory pathology. Expression of TRPM8 was repeatedly reported to be upregulated in the respiratory tract of asthma and COPD patients both at mRNA and protein level [35–37]. Besides smoke, this channel is also capable of activation by cold temperature and menthol [7]. Stimulation of TRPM8 in the airways is typically accompanied by inflammatory reaction including cytokine production, cellular infiltration and mucus hypersecretion [35,37–39]. As compared to TRPM8, the TRPA1 channel, aptly named ‘a gatekeeper of inflammation’ [40], is less studied in real clinical respiratory pathology, probably due to its limited expression in the airway epithelium. At the same time, TRPA1 is abundantly expressed in nerve endings, alveolar epithelium and fibroblasts where it mediates neurogenic and non-neurogenic inflammation upon activation [41,42].

In the present study we investigated the role of TRPM8 and TRPA1 genetic polymorphisms in the development of COPD in smoking subjects and explored their effect on lung function in COPD patients. We established that TRPM8 rs2052030 polymorphism may influence predisposition to COPD development in the over-dominant genetic model. Carriers of the heterozygous CG genotype were relatively protected against COPD in spite of smoking. This effect was independent of sex, age or smoking history, but was not significant after correction for multiple testing. Previously, the only relevant study conducted by Xiong et al. [17] in the Chinese Han population also revealed several TRPM8 polymorphisms associated with COPD and pulmonary hypertension. However, due to significant difference in allelic frequencies, we were unable to directly replicate the obtained results.

Another finding of this study indicates that the TRPA1 rs7819749 polymorphism significantly influences lung function in COPD patients. Correlation analysis showed that the degree of bronchial obstruction had a tendency to aggravation with the increase in the number of the T alleles. In addition, we replicated the effect of TRPM8 rs11562975 on lung function that was previously found in smoking asthma patients [33]. There are no previous studies that estimated the influence of TRPM8 and TRPA1 polymorphisms on lung function in COPD, so the identified associations are now reported for the first time. Gallo et al. [31] and Kotova et al. [43] described linkage between TRPA1 polymorphisms and the development of asthma in children and adults. However, in the former study the T allele of rs959974 increased the risk of childhood asthma, while we found that it was rather protective against excessive deterioration of lung function in COPD. TRPM8 rs11562975 is another polymorphism with well documented functional significance. The C allele was consistently reported to determine increased sensitivity to local skin cooling [44,45], bronchoconstriction in response to cold air inhalation [27] or severe bronchial obstruction in smoking asthma patients [33]. These results are in perfect agreement with the data obtained in this study—the C allele carriers were prone to enhanced bronchial obstruction as measured by FEV1/FVC ratio and significantly prevailed among COPD patients with post-bronchodilator FEV1 < 60% independently on the other factors.
Finally, we unexpectedly found that TRPA1 rs959976 and TRPM8 rs17865682 polymorphisms may alter the airway response to β2-adrenergic agonist salbutamol. It is difficult to draw firm conclusions regarding the molecular mechanisms explaining this effect, although interactions between G protein-coupled receptors and TRP channels are quite common [46]. It was also established that rs959976 is associated with migraine onset before the age of 15 and can modulate the response of TRPA1 to coal fly ash [32,47].

Relatively small sample size is the main limitation of this study. Nevertheless, substantiated hypothesis and choice of polymorphisms, consistent significance of the obtained associations after correction for possible confounding factors and repetitive confirmation of TRPM8 rs11562975 effect in independent samples increase the likelihood of the results’ reliability.

5. Conclusions

In conclusion, in the present study we discovered the variants of TRPM8 and TRPA1 genes that may probably influence COPD predisposition and lung function in European population which suggests the potential importance of these cationic channels in COPD pathogenesis. The heterozygous genotype of TRPM8 rs2052030 tended to protect smokers from COPD development. In COPD patients, TRPA1 rs7819749 influenced the degree of bronchial obstruction measured both before and after the inhalation of bronchodilator. In addition, we replicated the effect of TRPM8 rs11562975 on lung function and established the associations of TRPA1 rs959976 and TRPM8 rs17865682 polymorphisms with changes in salbutamol response. Future studies are suggested not only to verify the role of TRPM8 and TRPA1 polymorphisms in a larger sample but also to provide functional evidence for the observed effect of allelic variants at molecular level.

Supplementary Materials: The following are available online at https://www.mdpi.com/2075-4426/11/2/108/s1, Table S1: Detailed conditions of TRPM8 and TRPA1 polymorphisms genotyping.

Author Contributions: Conceptualization, D.E.N.; Data curation, O.O.K., D.A.G. and E.Y.A.; Formal analysis, O.O.K.; Investigation, O.O.K., D.A.G., I.Y.S., E.Y.A. and E.G.S.; Methodology, D.E.N.; Resources, E.G.S.; Supervision, J.M.P.; Visualization, D.A.G.; Writing—original draft, I.Y.S.; Writing—review & editing, D.E.N.; All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Ministry of Science and Higher Education of the Russian Federation under the Program for Basic Research (0420-2019-0006).

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the local Ethics Committee of Far Eastern Scientific Center of Physiology and Pathology of Respiration (Ethic approval No. 131; 11 January 2019).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data supporting this study are available on request from the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References
1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Diagnosis, Management, and Prevention of COPD. 2010. Available online: http://www.goldcopd.org/ (accessed on 28 November 2013).
2. Adeloye, D.; Chua, S.; Lee, C.; Basquill, C.; Papania, A.; Theodoratou, E.; Nair, H.; Gasevic, D.; Sridhar, D.; Campbell, H.; et al. Global and regional estimates of COPD prevalence: Systematic review and meta–analysis. J. Glob. Health 2015, 5, 020415. [CrossRef]
3. Lortet-Tieulent, J.; Soerjomataram, I.; López-Campos, J.L.; Ancochea, J.; Coebergh, J.W.; Soriano, J.B. International trends in COPD mortality, 1995–2017. Eur. Respir. J. 2019, 54, 1901791. [CrossRef]
4. Mirza, S.; Benzo, R.P. Chronic Obstructive Pulmonary Disease Phenotypes: Implications for Care. Mayo Clin. Proc. 2017, 92, 1104–1112. [CrossRef] [PubMed]
26. Naumov, D.; Kotova, O.; Gassan, D.; Prikhodko, A.; Kolosov, V. Sex-Dependent Effect of TRPM8 rs10166942 Polymorphism on smokers and non-smokers: The Rotterdam Study. *Eur. J. Epidemiol.* **2016**, *31*, 785–792. [CrossRef]

28. Naumov, D.E.; Gassan, D.A.; Kotova, O.O.; Prikhodko, A.G.; Perelman, J.M.; Kolosov, V.P. Polymorphism of TRPM8 gene as an independent factor of bronchial obstruction in asthma. *Bull. Physiol. Pathol. Respir.* **2019**, *171*, 229–238. [CrossRef] [PubMed]

29. Naumov, D.E.; Kotova, O.O.; Gassan, D.A.; Prikhodko, A.G.; Perelman, J.M.; Kolosov, V.P. Role of TRPM8 polymorphisms in the formation of asthma phenotype with cold airway hyperresponsiveness. *Bull. Physiol. Pathol. Respir.* **2017**, *1*, 16–23. [CrossRef]
30. Binder, A.; May, D.; Baron, R.; Maier, C.; Tölle, T.R.; Treede, R.D.; Berthele, A.; Faltraco, F.; Flor, H.; Gierthmühlen, J.; et al. Transient receptor potential channel polymorphisms are associated with the somatosensory function in neuropathic pain patients. *PLoS ONE* **2011**, *6*, e17387. [CrossRef]  
31. Gallo, V.; Dijk, F.N.; Holloway, J.W.; Ring, S.M.; Koppelman, G.H.; Postma, D.S.; Strachan, D.P.; Granell, R.; De Jongste, J.C.; Jaddoe, V.W.; et al. TRPA1 gene polymorphisms and childhood asthma. *Pediatr. Allergy Immunol.* **2016**, *28*, 191–198. [CrossRef] [PubMed]  
32. Deering-Rice, C.E.; Shapiro, D.; Romero, E.G.; Stockmann, C.; Bevans, T.S.; Phan, Q.M.; Stone, B.L.; Fassl, B.; Nkoy, F.; Uchida, D.A.; et al. Activation of Transient Receptor Potential Ankyrin-1 by Insoluble Particulate Material and Association with Asthma. *Am. J. Respir. Cell Mol. Biol.* **2015**, *53*, 893–901. [CrossRef]  
33. Gassan, D.A.; Naumov, D.E.; Kotova, O.O.; Prikhodko, A.G.; Kolosov, V.P. TRPM8 gene polymorphism and smoking as the factors of severe bronchial obstruction in patients with asthma. *Bull. Physiol. Pathol. Respir.* **2017**, *1*, 24–30. [CrossRef]  
34. Kim, J.; Kim, W.J.; Lee, C.H.; Lee, S.H.; Lee, M.G.; Shin, K.C.; Yoo, K.H.; Lee, J.H.; Lim, S.Y.; Na, J.O.; et al. Which bronchodilator reversibility criteria can predict severe acute exacerbation in chronic obstructive pulmonary disease patients? *Respir. Res.* **2017**, *18*, 107. [CrossRef] [PubMed]  
35. Li, M.; Li, Q.; Yang, G.; Kolosov, V.P.; Perelman, J.M.; Zhou, X.D. Cold temperature induces mucin hypersecretion from normal human bronchial epithelial cells in vitro through a transient receptor potential melastatin 8 (TRPM8)–mediated mechanism. *J. Allergy Clin. Immunol.* **2011**, *128*, 626–634. [CrossRef] [PubMed]  
36. Kolosov, V.; Naumov, D.; Gassan, D.; Kilimichenko, K.; Afanaseva, E.; Sheludko, E.; Zhou, X-D. TRPM8 is overexpressed in the respiratory tract of steroid-naive asthma patients. *Asian Pac. J. Trop. Med.* **2018**, *11*, 16. [CrossRef]  
37. Kim, J.H.; Jang, Y.S.; Kim, H.I.; Park, J.Y.; Park, S.H.; Hwang, Y.L.; Jang, S.H.; Jung, K.S.; Park, H.S.; Park, C.S. Activation of Transient Receptor Potential Melastatin Family Member 8 (TRPM8) Receptors Induces Proinflammatory Cytokine Expressions in Bronchial Epithelial Cells. *Allergy Asthma Immunol. Res.* **2020**, *12*, 684–700. [CrossRef]  
38. Liu, H.; Liu, Q.; Hua, L.; Pan, J. Inhibition of transient receptor potential melastatin 8 alleviates airway inflammation and remodeling in a murine model of asthma with cold air stimulus. *Acta Biochim. et Biophys. Sin.* **2018**, *50*, 499–506. [CrossRef] [PubMed]  
39. Wang, J.; Yang, G.; Li, M.; Zhou, X. Transient Receptor Potential Melastatin 8 (TRPM8)-Based Mechanisms Underlie Both the Cold Temperature-Induced Inflammatory Reactions and the Synergistic Effect of Cigarette Smoke in Human Bronchial Epithelial (16HBE) Cells. *Front. Physiol.* **2019**, *10*, 285. [CrossRef]  
40. Bautista, D.M.; Pellegrino, M.; Tsunozaki, M. TRPA1: A Gatekeeper for Inflammation. *Annu. Rev. Physiol.* **2013**, *75*, 181–200. [CrossRef]  
41. Nassenstein, C.; Kwong, K.; Taylor-Clark, T.; Kollarik, M.; MacGlashan, D.M.; Braun, A.; Undem, B.J. Expression and function of the ion channel TRPA1 in vagal afferent nerves innervating mouse lungs. *J. Physiol.* **2008**, *586*, 1595–1604. [CrossRef]  
42. Nassini, R.; Pedretti, P.; Moretto, N.; Fusi, C.; Carnini, C.; Facchinetti, F.; Visconti, A.R.; Pisano, A.R.; Stokesberry, S.; Brunmark, C.; et al. Transient Receptor Potential Ankyrin-1 Channel Localized to Non-Neuronal Airway Cells Promotes Non-Neurogenic Remodeling in a Murine Model of Asthma. *Bull. Physiol. Pathol. Respir.* **2017**, *128*, 598–607. [CrossRef]  
43. Kozyreva, T.V.; Tkachenko, E.Y.; Potapova, T.A.; Romashchenko, A.G.; Voevoda, M.I. Single-nucleotide polymorphism rs11562975 of the TRPM8 temperature-sensitive ion channel gene. *Hum. Physiol.* **2018**, *7*, e42454. [CrossRef]  
44. Kotova, O.O.; Gassan, D.A.; Naumov, D.E.; Sheludko, E. Effect of TRPA1 gene polymorphisms on predisposition to the formation of bronchial asthma. *Bull. Physiol. Pathol. Respir.* **2019**, *73*, 27–33. [CrossRef]  
45. Kozyreva, T.V.; Tkachenko, E.Y.; Potapova, T.A.; Voevoda, M.I. Single-nucleotide polymorphism rs11562975 of the thermosensitive ion channel TRPM8 gene and human sensitivity to cold and menthol. *Hum. Physiol.* **2011**, *37*, 188–192. [CrossRef]  
46. Kozyreva, T.V.; Tkachenko, E.Y.; Potapova, T.A.; Voevoda, M.I. Respiratory system response to local cooling in subjects with single nucleotide polymorphism rs11562975 of the TRPM8 temperature-sensitive ion channel gene. *Hum. Physiol.* **2014**, *40*, 197–200. [CrossRef]  
47. Veldhuis, N.A.; Poole, D.P.; Grace, M.; McIntyre, P.; Bunnell, N.W. The G Protein–Coupled Receptor–Transient Receptor Potential Channel Axis: Molecular Insights for Targeting Disorders of Sensation and Inflammation. *Pharmacol. Rev.* **2015**, *67*, 36–73. [CrossRef] [PubMed]  
48. Kowalska, M.; Prendecki, M.; Kapeluski-Pielok, M.; Grzelak, T.; Lagan-Jędrzejczyk, U.; Wisniewska, M.; Kozubski, W.; Dorszewska, J. Analysis of Genetic Variants in SCN1A, SCN2A, KCNK18, TRPA1 and STX1A as a Possible Marker of Migraine. *Curr. Genom.* **2020**, *21*, 224–236. [CrossRef]